Erasca is looking for a refresh as it drops several early-stage cancer assets, picks up new ones from China and raises cash to help push its lead candidate to the finish line. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER